From Yahoo Finance: 2025-05-04 05:38:00

Last week, Hims & Hers Health, Inc. (HIMS) surged by 45.3% to $40.82, driven by a new partnership with Novo Nordisk. Investors eagerly await the company’s first quarter earnings report on May 5 for updated guidance. HIMS ranks 2nd on the list of top-performing firms, but AI stocks may offer greater returns.

The tech-heavy Nasdaq led the market rally last week, climbing 3.4%, followed by the Dow Jones at 3% and the S&P 500 at 2.9%. Amid a positive market environment and strong corporate earnings, 10 mid-cap companies stood out with double-digit gains, fueled by impressive earnings and outlook.

Hims & Hers Health, Inc. (HIMS) recently secured a long-term partnership with Novo Nordisk to market the weight loss drug Wegovy. Americans can now access NovoCare Pharmacy through HIMS’ platform, offering Wegovy and a Hims & Hers membership with 24/7 care and nutrition guidance. HIMS’ previous knock-off version of Wegovy was discontinued after FDA approval.

10 firms, including HIMS, soared last week due to better-than-expected earnings and outlook. HIMS’ partnership with Novo Nordisk drove its 45.3% surge, positioning it as the 2nd best-performing company. While HIMS shows potential, investing in AI stocks may offer higher returns in a shorter timeframe.

Read more: Why Hims & Hers Health, Inc. (HIMS) Soared Last Week